Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis
Authors' conclusion
Teprotumumab effectively reduces proptosis, improves diplopia, and lowers disease activity in TED, regardless of previous treatments, severity, or dosage, albeit with increased AEs. It has the potential to become a vital first-line treatment for TED, enhancing patient quality of life.
Study context
- Population
- Patients with thyroid eye disease (TED) (Graves' orbitopathy); studies from PubMed, Web of Science, EMBASE, Cochrane library and ClinicalTrials.gov up to January 1, 202410 studies: 4 RCTs, 6 observational
- Participants
- 210 vs 193
- Comparison
- Teprotumumab vs placebo
- Teprotumumabn = 210
- Placebon = 193reference
- Outcome
- Efficacy in RCTs
Pooled result
As reported in the abstract
Relative risk (CI)
Teprotumumabvs Placeboproptosis response
4.18(2.72–6.43)
Teprotumumabvs Placebodiplopia regression
2.29(1.54–3.41)
Teprotumumabvs PlaceboCAS score
3.09(1.98–4.80)
SMD (CI)
Between Teprotumumab and Placeboproptosis reduction
−8.38(−9.25 - −7.52)
Further pooled results
Observational studies (teprotumumab, single group)
- Patients
- 211
- Proptosis response rate
- 82%
- Change in proptosis
- −3.31 mm
- Diplopia improvement rate
- 0.58
- Pooled effect size for Clinical Activity Score (CAS) score
- 0.66
- 6 observational studies
Safety
Adverse events (AEs) and serious AEs (RCTs)
- Risk of AEs and serious AEs higher with teprotumumab
AEs and serious AEs (observational studies)
- AE incidence
- 0.78
- Serious AEs
- 0.31
Original publication
Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A Systematic Review and Meta-Analysis. Endocr Pract. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →